Back to top
more

VAREX IMAGING (VREX)

(Delayed Data from NSDQ)

$14.29 USD

14.29
322,132

-0.06 (-0.42%)

Updated Jul 8, 2024 04:00 PM ET

After-Market: $14.28 -0.01 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 249)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Abbott (ABT) Nutrition Sales Strong Amid Spike in COVID Cases

by Zacks Equity Research

Abbott (ABT) is registering strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.

NEOGEN (NEOG) Strengthens Global Foothold With Delf Buyout

by Zacks Equity Research

NEOGEN (NEOG) management believes that Delf's 40 years of experience in the UK dairy hygiene market will help it strengthen its foothold in this region's dairy chemicals market.

Walgreens Boots (WBA) Faces Margin Pressure, Solvency Issue

by Zacks Equity Research

Of late, increased reimbursement pressure and generic drug cost inflation have been hampering Walgreens Boots' (WBA) margin significantly.

Henry Schein (HSIC) Introduces Treatment Planning Software

by Zacks Equity Research

The Studio Pro 4.0 launched by Henry Schein's (HSIC) orthodontics business will enable Reveal Clear Aligners providers to personalize treatment plans with greater ease and control.

Medtronic (MDT) Gets Health Canada License for GI Genius Module

by Zacks Equity Research

Medtronic Canada ULC, a subsidiary of Medtronic (MDT), receives Health Canada license for the GI Genius module that aids in colorectal cancer screening.

Here's Why You Should Invest In Bruker (BRKR) Stock for Now

by Zacks Equity Research

Investors are optimistic about Bruker's (BRKR) better-than-expected results and strong segmental performance.

QIAGEN (QGEN), DiaSorin to Broaden Access to Latent TB Testing

by Zacks Equity Research

QIAGEN (QGEN) and DiaSorin gained FDA approval for their jointly-created LIAISON QuantiFERON-TB Gold Plus assay for use on DiaSorin's automated LIAISON XS platform.

Here's Why You Should Hold on to Globus Medical (GMED) for Now

by Zacks Equity Research

Investors are optimistic about Globus Medical's (GMED) better-than-expected earnings and robust ExcelsiusGPS performance.

Here's Why You Should Retain ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors are optimistic about ResMed (RMD) given its better-than-expected results and robust SaaS business performance in the fiscal first quarter.

Smith+Nephew (SNN) Introduces Real Intelligence & CORI System

by Zacks Equity Research

Smith+Nephew (SNN) debuts new brand of enabling technology solutions as well as its next-generation handheld robotics platform in Canada.

Quest Diagnostics' (DGX) Base Volumes Rise, Testing Recovers

by Zacks Equity Research

Contributions from new hospital lab management contracts as well as people returning to the healthcare system aid Quest Diagnostics (DGX).

Medtronic (MDT) Gets CE Mark for Radial Artery Access Portfolio

by Zacks Equity Research

Medtronic's (MDT) Rist Radial Access Catheters are indicated for the introduction of interventional devices into the peripheral, coronary and neuro vasculature.

Here's Why You Should Retain Insulet (PODD) Stock for Now

by Zacks Equity Research

Strong domestic and international performance by Omnipod is driving the top line for Insulet (PODD).

CVS Health (CVS) Retail Business Grows Despite Cost Pressure

by Zacks Equity Research

CVS Health's (CVS) retail business sees solid rebound in front-store sales with strength across all categories.

SmileDirectClub (SDC) to Boost Europe Presence, Enter France

by Zacks Equity Research

SmileDirectClub (SDC) since its foray into Europe in 2019 has been seeing remarkable market penetration of its oral care products.

Neogen (NEOG) Q1 Earnings Top Estimates, Gross Margin Up

by Zacks Equity Research

Strong segmental performance and contributions from new acquisitions and product launches drove Neogen's (NEOG) revenues in the first quarter of fiscal 2022.

Boston Scientific (BSX) Strategic Buyouts Aid Amid Cost Woes

by Zacks Equity Research

Boston Scientific (BSX) is optimistic about its recent deal to acquire Israel-based Lumenis that develops and commercializes energy-based medical solutions.

Boston Scientific's (BSX) New Buyout to Aid Clot Management

by Zacks Equity Research

The acquisition of Devoro Medical by Boston Scientific (BSX) is expected to advance the company's core emphasis on clot management.

NEOGEN (NEOG) to Enter Retail Parasiticide Space With New Buyout

by Zacks Equity Research

NEOGEN's (NEOG) acquisition of CAPInnoVet expands its Animal Safety division and offers a strategic entry into the retail parasiticide market.

Quest Diagnostics' (DGX) COVID-19 Test Demand Up in Q3 Months

by Zacks Equity Research

The "Path Out of the Pandemic" plan of the U.S. Government, while emphasizing more on a magnified access for testing, comes as a major breakthrough for Quest Diagnostics (DGX).

Stryker's (SYK) Trauma & Extremities Arm Unveils New Product

by Zacks Equity Research

The newly launched Citrelock Tendon Fixation Device System expands Stryker's (SYK) Foot & Ankle offerings.

Here's Why You Should Retain National Vision (EYE) For Now

by Zacks Equity Research

Investors are optimistic about National Vision (EYE) owing to new store growth and pandemic-induced increase in demand for the company's offerings.

Here's Why You Should Retain Boston Scientific (BSX) for Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX) given a strong second-quarter performance and strength in the Structural Heart business.

Quest Diagnostic (DGX) Raises View on COVID-19 Testing Surge

by Zacks Equity Research

Going by the current situation of daily increase in the coronavirus case count, Quest Diagnostics (DGX) expects COVID-19 molecular testing volumes to remain stronger through the rest of the year.

ResMed (RMD)-Backed Landmark ALASKA Study Favors PAP Therapy

by Zacks Equity Research

A late-breaking abstract from ResMed (RMD) supported landmark ALASKA study reported that treatment with PAP therapy improves the likelihood of longevity in sleep apnea patients